This table summarises the latest information provided by companies regarding the prices at which they are currently offering antiretrovirals to resource-poor countries, and the terms of the offers.
Some of these offers are being made through the UNAIDS Accelerating Access Initiative; others are being offered through programmes established by the companies themselves.
We will update this table regularly as more information becomes available. Any information on prices of generic alternatives would be welcomed; despite repeated efforts over the past few weeks we have been unable to establish the prices offered by manufacturers of generic antiretrovirals.
|
Generic name |
Brand name |
Initials |
Manufacturer |
Discount price |
Special provisions |
Generic alternative |
|
Lopinavir/ritonavir |
Kaletra |
N/a |
Abbott |
c.$1,000 per year |
Africa (available to private sector or company health plans and NGOs, as well as govts) |
None |
|
Ritonavir |
Norvir |
N/a |
Abbott |
c. $1,000 |
Africa (available to private sector or company health plans and NGOs, as well as govts) |
India |
|
Saquinavir |
Fortovase |
N/a |
Roche |
c. $1300 if dosed once daily with ritonavir, or $2400 if dosed at 1200mg three times daily |
Available to least developed nations at negotiable prices - Roche is seeking to offer the drug at cost and offer research grants to those providing clinical care |
none |
|
Indinavir |
Crixivan |
N/a |
Merck |
$600 per year |
Africa Romania Haiti Brazil Available to NGOs and company health plans, as well as govts |
|
|
efavirenz |
Stocrin |
N/a |
Merck |
$500 per year |
Africa Romania Haiti Brazil Available to NGOs and company health plans, as well as govts |
|
|
stavudine |
Zerit |
D4T |
Bristol Myers Squibb |
15 cents a day/$54 per year |
Not available to private sector/company health plans |
Thailand Brazil India |
|
didanosine |
Videx |
ddI |
Bristol Myers Squibb |
80 cents per day |
Not available to private sector/ company health plans |
Not patented in Africa Thailand Brazil India |
|
nevirapine |
Viramune |
Boehringer Ingelheim |
Free as two doses for mother and infant treatment $1.22 per day for adult dosing ($445 p.a) |
Maternal/infant treatment free to all non-EU countries (also excludes USA, Canada, NZ, Australia, Japan, Switzerland, Norway, Iceland) |
India: Cipla (Nevimune$340 p.a) |
|
|
Zidovudine and lamivudine |
Combivir |
AZT and 3TC |
Glaxo Smith Kline |
$2 per day |
Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDS Accelerating Access Initiative |
Brazil India |
|
Zidovudine |
Retrovir |
AZT |
Glaxo Smith Kline |
95% reduction on "average global price" |
As above |
Brazil India |
|
Abacavir |
Ziagen |
N/a |
Glaxo Smith Kline |
As above |
As above |
none |
|
Lamivudine |
Epivir |
3TC |
Glaxo Smith Kline |
58 cents per day |
As above |
Brazil India |
|
zalcitabine |
Hivid |
ddC |
Roche |
Available at cost |
Brazil |